CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma
Publication date: Available online 8 April 2020Source: Pharmacological ResearchAuthor(s): Yanan Gao, Xing Fan, Nan Li, Chengzhi Du, Bin Yang, Wenhao Qin, Jing Fu, Geoffrey J. Markowitz, Hongyang Wang, Jianli Ma, Shuqun Cheng, Pengyuan Yang
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer